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The optimal treatment of lung cancer relies on accurate histopathologic diagnosis. Thisis usually accomplished with a limited amount of tissue, on which multiple tests must
be performed to enable the histologic, immunohistochemical, and molecular character-
ization of tumors. In this issue of the journal, Travis1 has succeeded in his attempt to
“think like the clinician” by better pathologically classifying adenocarcinoma. His success
will facilitate the most appropriate treatment for patients with non-small cell lung cancer
(NSCLC). Although interest in this subject must have been present for some time, several
events accelerated the need for such a document. The first was the increased availability
and use of chest computed tomography, which led to the identification of early-stage
tumors with distinct radiographic features, some of which could not have been identified
in the era of chest radiographs. A proportion of these lesions (e.g., ground glass opacities)
could not be adequately defined by the previously available pathologic definitions.
Further, the clinical behavior of these tumors was distinctly different when compared with
the more commonly seen invasive cancers. Second, molecular aberrations with prognostic
and predictive significance were identified and needed to be considered to optimize
histopathological diagnoses.2,3 Third, the recent findings that commonly used therapeutic
agents can selectively benefit patients with specific histologic phenotype, and molecular
characteristics created the need for better definitions of NSCLC, particularly adenocarci-
noma, which was addressed in this document.4–6
NSCLCs are clinically, pathologically, and molecularly heterogeneous entities. This
diverse group, often with overlapping features, makes the demarcation of NSCLCs into
histopathologically distinct subentities challenging. Nevertheless, successfully accom-
plishing this has never been so important because treatment selection is now integrally
dependent on the histologic phenotype and the molecular genotype. The authors have
attempted to accomplish this by tackling potential “areas of confusion” for practicing
pathologists, radiologists, and clinicians.
It is critically important to emphasize that obtaining adequate amounts of tissue at
the time of diagnosis is essential, so that second interventional biopsies can be eliminated.
Clinicians can no longer be satisfied with a diagnosis of NSCLC when making treatment
decisions. Nevertheless, there are opposing forces at work as it relates to tissue acquisition
and processing. On the one hand, minimally invasive access to tumor using technologies
such as endobronchial ultrasound guided or transthoracic needle biopsy is increasing at a
time when more tests need to be performed with each specimen. Reverting back to more
invasive techniques for obtaining a larger volume of tissue for comprehensive testing is
unrealistic. Therefore, the onus is on us to develop instruments that provide minimally
invasive access while enabling pathologists to receive adequate tissue for analysis.
The optimal utilization of tissue is also paramount. In most patients, histomorpho-
logical and molecular features can be appropriately characterized. The team must decide
how to optimally use the available tissue. Travis tackled this problem by suggesting that
pathologists minimize the use of immunohistochemical stains, so that more tissue is
available for molecular diagnosis. We concur with this recommendation because treatment
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decisions are becoming increasingly dependent on the
presence or absence of certain molecular markers. As
additional molecular aberrations of clinical relevance are
identified, this strategy will become even more germane.
Algorithms should be developed where the testing for
molecular markers of interest is prioritized in a stepwise
fashion. Currently, the status of epidermal growth factor
receptor mutations,5 EML-4 ALK translocation2 and Kras
mutation, are of clinical significance.7
Nevertheless, as much as possible, clarifying the areas
of confusion is imperative. One major area of uncertainty is
the definition of what was formerly referred to as bronchi-
oloalveolar carcinoma and its various subtypes. The panel has
recommended that the term bronchioloalveolar carcinoma be
eliminated and replaced by adenocarcinoma in situ or inva-
sive mucinous adenocarcinoma. This new terminology pro-
vides a description that clinicians are already familiar with,
that is, a progression from dysplasia, to in situ carcinoma to
invasive carcinoma. These proposed changes provide more
rational definitions that correlate with the clinical and radio-
graphic presentation of patients with NSCLC and also could
influence treatment decision-making.
Another pathologic subtype of NSCLC that has been
further clarified is the definitions of large cell carcinoma. The
authors propose classifying large cell carcinoma with neu-
roendocrine features defined by immunohistochemical stain-
ing as a distinct entity, namely large cell carcinoma with
neuroendocrine morphology. This has important clinical im-
plications because large cell carcinoma with neuroendocrine
morphology may be better treated with a regimen directed at
small cell lung cancer. Large cell carcinomas without neu-
roendocrine features are now classified as NSCLC—not oth-
erwise specified and may be better treated with pemetrexed-
containing regimens.6
We envision a future in which patients are diagnosed
and staged for their lung cancer using a much more rigorous
approach. Rather than prescribing treatment for a patient with
“stage IV NSCLC,” clinicians should move toward describ-
ing the same patient as T2N2M1a, stage IV, invasive muci-
nous adenocarcinoma, epidermal growth factor receptor,
and Kras. The new classification system for adenocarci-
noma described herein provides one of the missing pieces
needed to accomplish that goal and allows for the personal-
ized treatment of lung cancer. We applaud this effort because
you just cannot call it lung cancer anymore.
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